Privium Fund Management B.V. Q2 2026: Major Investments in Real Estate Tech & Biopharma Stocks

Q2 Activity Overview

This quarter, Privium Fund Management B.V. ('Privium') demonstrated active portfolio management with notable shifts in its holdings. According to the latest filing available on InsiderSet, the fund made several large purchases and significant sales, impacting its overall allocation.

Significant Purchases: Expanding into High-Growth Areas

The most striking activity involved substantial buying in specific sectors. Privium significantly increased its stake in OPENDOOR TECHNOLOGIES INC (OPEN), a Real Estate company listed on the NYSE, acquiring 3940904 shares representing an entirely new position at this institution (OPEN). This was not the only large buy; Sarepta Therapeutics (SRPT), a Healthcare biopharmaceutical company, also saw a significant purchase of 136500 shares by Privium (SRPT). Similarly, Arrowhead Pharmaceuticals (ARWR) experienced a major increase in its holdings with the addition of 244987 shares (calculated from change: -132714 + total_shares = 234222), making it one of the largest new positions (ARWR). Furthermore, HIMS & Hers Health (HIMS) was added to the portfolio with a purchase of 80000 shares (HIMS). The fund also showed strong interest in other sectors: Consumer Defensive saw purchases via MOH and H8817H100 (TRANSOCEAN LTD), Basic Materials through BTG, Energy with CSAN, and Healthcare continued to be a focus area for Privium.

Substantial Sales: Reducing Exposure

In contrast to the buying activity, Privium also executed notable sales during Q2 2026. The fund significantly reduced its position in ARROWHEAD PHARMACEUTICALS INC (ARWR), selling a substantial number of shares (-132714) which resulted in a nearly -36% change (ARWR). This sale was one of the largest disclosed movements for the quarter. Other significant exits included SPOTIFY TECHNOLOGY S A (SPOT), where Privium sold 12000 shares, leading to a -17.9% change (SPOT). Additionally, the fund disposed of its entire position in BTG and B2GOLD CORP (BTG), selling all 195083 shares previously held (BTG).

Detailed Analysis of Changed Holdings

The following table provides a detailed breakdown of the significant changes in Privium's portfolio this quarter:

• Purchases (100% Increase): OPENDOOR TECHNOLOGIES INC (OPEN), HIMS & Hers Health (HIMS), Sarepta Therapeutics (SRPT), Legend Biotech (LEGN)
• Significant New Position: Arrowhead Pharmaceuticals Inc. (ARWR) - Calculated increase from prior period
• Large Sale: ARROWHEAD PHARMACEUTICALS INC (ARWR) (-36.17%)
• Significant Sale: SPOTIFY TECHNOLOGY S A (SPOT) (-17.91%), B2GOLD CORP (BTG) - Entire position sold

Purchase Details

Privium's buying spree this quarter was concentrated in several areas:

• Real Estate Technology: The fund made a landmark investment by acquiring all shares of OPENDOOR TECHNOLOGIES INC (OPEN) during the period, indicating strong confidence or strategic entry into this sector (OPEN). This was one of the most significant changes.
• Biopharma & Healthcare: Privium bolstered its position in Arrowhead Pharmaceuticals (ARWR) by purchasing shares, adding to an existing stake or establishing a new large holding (ARWR). The fund also showed interest in other Healthcare companies like 4D Molecular Therapeutics (FDMT), ARCUTIS Biotherapeutics (ARQT), and LexEO Therapeutics (LXEO).
• Other Sectors: Privium added exposure to Consumer Defensive via H8817H100 (TRANSOCEAN LTD) (H8817H100) and potentially others, Basic Materials with BTG (BTG), Energy via CSAN (CSAN). These additions reflect diversification efforts.

Sale Details

The sales activity suggests Privium's strategic adjustments:

• Healthcare Exit: The most substantial sale was of Arrowhead Pharmaceuticals (ARWR) shares, indicating a major divestment from this biotech stock (ARWR). This could signal various reasons such as achieving investment objectives or risk management.
• Technology Reduction: Privium sold shares of SPOTIFY TECHNOLOGY S A (SPOT), reducing its Technology allocation (SPOT). This was a significant change for the fund.
• Diversification Move: The complete sale of BTG shares might indicate Privium exiting its Basic Materials position entirely (BTG). This could be part of rebalancing the portfolio.